MNPR - Cash Flow Statement - Monopar Therapeutics Inc.

Millions

	Dec-2024	Dec-2023	Dec-2022	Dec-2021	Dec-2020	Dec-2019	Dec-2018	Dec-2017	Dec-2016	Dec-2015
OPERATING CASH FLOW
Net Income	(15.6)	(8.4)	(10.5)	(9.1)	(6.3)	(4.2)	(3.2)	(16.6)	(1.2)	(0.7)
Depreciation & Amortization	0	0	0	0	0	0	0	0	0	0
Deferred Income Tax	0	0	0	0	0	0	0	0	0	0
Stock Based Compensation	1.1	1.9	1.6	1.5	1.3	1.0	0.5	0.3	0	0
Other Operating Activities	4.6	0	0.2	1.1	(0.1)	0.8	0.4	13.5	9.33 K	73.8 K
Change in Working Capital	3.5	(1.4)	1.6	0.3	0.4	0.2	(0.2)	0.1	9.04 K	51 K
Cash From Operations	(6.4)	(7.9)	(7.2)	(7.3)	(4.7)	(3.0)	(2.9)	(2.6)	(1.2)	(0.6)
INVESTING CASH FLOW
Capital Expenditures	0	0	0	0	0	0	0	0	0	0
Other Items	(14.3)	4.9	(4.9)	0	0	0	0	0	0	0
Cash From Investing Activities	(14.3)	4.9	(4.9)	0	0	0	0	0	0	0
FINANCING CASH FLOW
Common Stock Repurchased	0	0	0	0	0	0	0	0	0	0
Total Debt Repaid	0	0	0	0	0.1	0	0	0	0	0
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Other Financing Activities	(0.1)	47 K	76.5 K	45.8 K	(0.1)	(0.9)	(0.2)	4.8	1.3	3.4
Cash From Financing Activities	59.3	2.0	32.9 K	10.9	8.2	9.3	(0.2)	9.5	1.3	3.4
CHANGE IN CASH
Net Change In Cash	38.6	(0.9)	(12.1)	3.6	3.5	6.3	(2.9)	6.9	67.9 K	2.8
FREE CASH FLOW
Free Cash Flow	(6.4)	(7.9)	(7.2)	(7.3)	(4.7)	(3.0)	(2.9)	(2.6)	(1.2)	(0.6)

Free